GB201617564D0 - Anti-p53 antibodies - Google Patents

Anti-p53 antibodies

Info

Publication number
GB201617564D0
GB201617564D0 GBGB1617564.8A GB201617564A GB201617564D0 GB 201617564 D0 GB201617564 D0 GB 201617564D0 GB 201617564 A GB201617564 A GB 201617564A GB 201617564 D0 GB201617564 D0 GB 201617564D0
Authority
GB
United Kingdom
Prior art keywords
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1617564.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Priority to GBGB1617564.8A priority Critical patent/GB201617564D0/en
Publication of GB201617564D0 publication Critical patent/GB201617564D0/en
Priority to SG11201903411YA priority patent/SG11201903411YA/en
Priority to US16/342,763 priority patent/US11613568B2/en
Priority to JP2019520556A priority patent/JP7173964B2/ja
Priority to PCT/SG2017/050522 priority patent/WO2018074978A1/en
Priority to CN201780078161.4A priority patent/CN110770252A/zh
Priority to EP17861395.6A priority patent/EP3526251A4/en
Priority to US18/172,773 priority patent/US12195526B2/en
Priority to US18/961,716 priority patent/US20250263475A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GBGB1617564.8A 2016-10-17 2016-10-17 Anti-p53 antibodies Ceased GB201617564D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB1617564.8A GB201617564D0 (en) 2016-10-17 2016-10-17 Anti-p53 antibodies
SG11201903411YA SG11201903411YA (en) 2016-10-17 2017-10-17 Anti-p53 antibodies
US16/342,763 US11613568B2 (en) 2016-10-17 2017-10-17 Anti-p53 antibodies
JP2019520556A JP7173964B2 (ja) 2016-10-17 2017-10-17 抗ｐ５３抗体
PCT/SG2017/050522 WO2018074978A1 (en) 2016-10-17 2017-10-17 Anti-p53 antibodies
CN201780078161.4A CN110770252A (zh) 2016-10-17 2017-10-17 抗p53抗体
EP17861395.6A EP3526251A4 (en) 2016-10-17 2017-10-17 Anti-p53 antibodies
US18/172,773 US12195526B2 (en) 2016-10-17 2023-02-22 Anti-p53 antibodies
US18/961,716 US20250263475A1 (en) 2016-10-17 2024-11-27 Anti-P53 Antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1617564.8A GB201617564D0 (en) 2016-10-17 2016-10-17 Anti-p53 antibodies

Publications (1)

Publication Number Publication Date
GB201617564D0 true GB201617564D0 (en) 2016-11-30

Family

ID=57680660

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1617564.8A Ceased GB201617564D0 (en) 2016-10-17 2016-10-17 Anti-p53 antibodies

Country Status (7)

Country Link
US (3) US11613568B2 (enExample)
EP (1) EP3526251A4 (enExample)
JP (1) JP7173964B2 (enExample)
CN (1) CN110770252A (enExample)
GB (1) GB201617564D0 (enExample)
SG (1) SG11201903411YA (enExample)
WO (1) WO2018074978A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110121268B (zh) * 2016-12-27 2023-01-31 希尔氏宠物营养品公司 宠物食品组合物
EP4077370A4 (en) * 2019-12-17 2024-02-28 The Johns Hopkins University MANA BODY TARGETING TUMOR ANTIGENS AND METHODS OF USE
GB202008688D0 (en) 2020-06-09 2020-07-22 Cancer Research Tech Ltd Chimeric antigen receptor cell
CN113403286B (zh) * 2021-06-24 2024-01-16 新乡学院 一种靶向性三展示噬菌体及其制备方法和应用
WO2023060115A1 (en) * 2021-10-05 2023-04-13 The Penn State Research Foundation Methods for treating cancers with mutated p53
CN116178501B (zh) * 2021-11-29 2025-08-29 深圳碳云智肽药物科技有限公司 靶向p53的多肽及其在制备用于治疗癌症的药物中的应用
EP4448583A4 (en) * 2021-12-16 2025-12-17 Univ Johns Hopkins MANABODIES AGAINST P53 TUMORANTIGENS AND METHOD FOR USE
TW202340474A (zh) * 2022-01-11 2023-10-16 大陸商深圳市珈鈺生物科技有限公司 樹突細胞腫瘤疫苗和其用途
CN114574524A (zh) * 2022-03-14 2022-06-03 深圳市体内生物医药科技有限公司 一种从全基因组中筛选肝癌抑癌基因的方法及其应用
WO2024178128A1 (en) * 2023-02-22 2024-08-29 Elysion Therapeutics, Inc. Lysis sensing receptors and uses thereof
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083709A (en) 1985-08-21 2000-07-04 Osi Pharmaceuticals, Inc. Immunoassay for detection of mutant P53 polypeptide in serum
JP3179481B2 (ja) 1990-06-27 2001-06-25 プリンストン ユニバーシティ 突然変異体ｐ５３検出用プローブ
AU1370592A (en) 1991-02-01 1992-09-07 Oncogene Science, Inc. Immunoassay for detection of mutant p53 polypeptide in biological fluids
US5646016A (en) 1991-02-06 1997-07-08 Genetics Institute, Inc. Peptide and protein fusions to thioredoxin, thioredoxin-like molecules, and modified thioredoxin-like molecules
DE69333448D1 (en) * 1992-07-22 2004-04-15 Univ Princeton P53 impfstoff
US20030086935A1 (en) * 1992-07-22 2003-05-08 Levine Arnold J. p53 vaccine
GB9224784D0 (en) * 1992-11-26 1993-01-13 Univ Dundee Cellular protein
US6630584B1 (en) 2000-03-16 2003-10-07 Ramot At Tel-Aviv University Ltd. Single chain antibody against mutant p53
JP2008533986A (ja) 2005-03-25 2008-08-28 ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド 変異型ｐ５３の共通エピトープに対するヒト合成単鎖抗体およびその使用
WO2009112075A1 (en) * 2008-03-13 2009-09-17 Universita' Degli Studi Di Trieste Peptides and aptamers thereof as specific modulators of mutant p53 function
US8728479B2 (en) * 2009-03-31 2014-05-20 The Trustees Of The University Of Pennsylvania Antigen-binding proteins comprising recombinant protein scaffolds
SG11201401043SA (en) 2011-09-09 2014-08-28 Agency Science Tech & Res P53 activating peptides

Also Published As

Publication number Publication date
SG11201903411YA (en) 2019-05-30
US12195526B2 (en) 2025-01-14
EP3526251A4 (en) 2020-06-10
WO2018074978A1 (en) 2018-04-26
US20230257457A1 (en) 2023-08-17
JP2019535241A (ja) 2019-12-12
JP7173964B2 (ja) 2022-11-16
EP3526251A1 (en) 2019-08-21
US20190248879A1 (en) 2019-08-15
CN110770252A (zh) 2020-02-07
US11613568B2 (en) 2023-03-28
US20250263475A1 (en) 2025-08-21

Similar Documents

Publication Publication Date Title
ZA201900373B (en) Anti-tim-3 antibodies
IL268517A (en) Anti-tigit antibodies
ZA201905966B (en) Anti-lag3 antibodies
SG11202000660QA (en) Anti-tigit antibodies
HUE067040T2 (hu) Anti-SIRPalfa antitestek
SG10201601719RA (en) Anti-LAG-3 Antibodies
ZA202002141B (en) Anti-transthyretin antibodies
GB201601073D0 (en) Antibodies
GB201709808D0 (en) Antibodies
GB201621439D0 (en) IL-11Ra Antibodies
GB201610044D0 (en) Antibodies
SG10201914130VA (en) GARP-TGF-β ANTIBODIES
GB201617564D0 (en) Anti-p53 antibodies
ZA201808317B (en) Anti-tnfrsf25 antibodies
GB201616699D0 (en) Antibodies
GB201603291D0 (en) Antibodies
ZA202003542B (en) Anti-alpha-synuclein antibodies
GB201720970D0 (en) Antibodies
IL271067A (en) Anti-trkb antibodies
PT3484921T (pt) Anticorpos anti-il-22r
IL260083A (en) Antibody against myl9
GB201711785D0 (en) Antibodies
GB201622197D0 (en) Antibodies
GB201620414D0 (en) Antibodies
GB201615224D0 (en) Antibodies

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)